Health
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place in Barcelona, Spain, from May 9–12, 2026. Eight presentations, including a late-breaking science oral presentation, are related to MYQORZO® (aficamten). Recently approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) by the U.S. Food
About this update from Cytokinetics, Incorporated
[{"type":"image","alt":"Cytokinetics, Incorporated","displaySize":"","headline":null,"caption":"Cytokinetics, Incorporated","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":131,"url":"https://media.zenfs.com/en/globenewswire.com/10a960ea96a50bea5c777e88dba3bc2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/J0pajxHwFe95Ug.L7DMD4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mw--/https://media.zenfs.com/en/globenewswire.com/10a960ea96a50bea5c777e88dba3bc2e","width":300,"height":131}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place in Barcelona, Spain, from May 9–12, 2026. Eight presentations, including a late-breaking science oral presentation, are related to MYQORZO® (aficamten). Recently approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) by the U.S. Food and Drug Administration, European Commission, and the China National Medical Products Administration, MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction.","length":838,"tagName":"p"},{"type":"text","content":"Late Breaking Science Oral Presentation","length":39,"tagName":"p"},{"type":"text","content":"Title: Dose-dependent effects of aficamten compared with metoprolol in obstructive HCM: the MAPLE-HCM studyPresenter: Pablo Garcia-Pavia, M.D., Ph.D., Head of the Inherited Cardiac Diseases and Heart Failure Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro and Full Professor at Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain Date: May 11, 2026Session Title: Advances in CardiomyopathiesSession Time: 3:30 PM – 4:30 PM CESTPresentation Time: 4:06 PM – 4:18 PM CESTLocation: Room 3","length":529,"tagName":"p"},{"type":"text","content":"Rapid Fire Presentations","length":24,"tagName":"p"},{"type":"text","content":"Title: Favorable Effect of Aficamten on Left Atrial Mechanics in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM TrialPresenter: Yasuhiro Hamatani, M.D., Ph.D., Post...